CA2762446A1 - Utilisation de la combinaison de molecules inhibitrices de la semaphorine-4d et de molecules inhibitrices du facteur de croissance vasculaire endotheliale afin d'inhiber l'angiogenese - Google Patents

Utilisation de la combinaison de molecules inhibitrices de la semaphorine-4d et de molecules inhibitrices du facteur de croissance vasculaire endotheliale afin d'inhiber l'angiogenese Download PDF

Info

Publication number
CA2762446A1
CA2762446A1 CA 2762446 CA2762446A CA2762446A1 CA 2762446 A1 CA2762446 A1 CA 2762446A1 CA 2762446 CA2762446 CA 2762446 CA 2762446 A CA2762446 A CA 2762446A CA 2762446 A1 CA2762446 A1 CA 2762446A1
Authority
CA
Canada
Prior art keywords
vegf
sema4d
ser
antibody
leu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA 2762446
Other languages
English (en)
Other versions
CA2762446C (fr
Inventor
Ernest S. Smith
Elizabeth E. Evans
John R. Basile
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vaccinex Inc
Original Assignee
Vaccinex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vaccinex Inc filed Critical Vaccinex Inc
Publication of CA2762446A1 publication Critical patent/CA2762446A1/fr
Application granted granted Critical
Publication of CA2762446C publication Critical patent/CA2762446C/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Landscapes

  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Il est décrit des procédés dinhibition de langiogenèse tumorale chez un patient cancéreux, le procédé comprenant ladministration au sujet dune quantité efficace dune première molécule de liaison isolée qui se lie spécifiquement à la sémaphorine-4D (SEMA4D) et dune quantité efficace dune seconde molécule de liaison isolée qui se lie spécifiquement au VEGF.
CA2762446A 2011-12-06 2011-12-15 Utilisation de la combinaison de molecules inhibitrices de la semaphorine-4d et de molecules inhibitrices du facteur de croissance vasculaire endotheliale afin d'inhiber l'angiogenese Active CA2762446C (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161567531P 2011-12-06 2011-12-06
USUS61/567,531 2011-12-06

Publications (2)

Publication Number Publication Date
CA2762446A1 true CA2762446A1 (fr) 2013-06-06
CA2762446C CA2762446C (fr) 2021-02-23

Family

ID=48570515

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2762446A Active CA2762446C (fr) 2011-12-06 2011-12-15 Utilisation de la combinaison de molecules inhibitrices de la semaphorine-4d et de molecules inhibitrices du facteur de croissance vasculaire endotheliale afin d'inhiber l'angiogenese

Country Status (1)

Country Link
CA (1) CA2762446C (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105492016A (zh) * 2013-06-25 2016-04-13 瓦西尼斯公司 脑信号蛋白-4d抑制分子与免疫调节治疗联用以抑制肿瘤生长和转移的应用
CN109073660A (zh) * 2016-02-29 2018-12-21 麦恩泰科特有限公司 可用于治疗湿性年龄相关性黄斑变性的预测性标志物

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105492016A (zh) * 2013-06-25 2016-04-13 瓦西尼斯公司 脑信号蛋白-4d抑制分子与免疫调节治疗联用以抑制肿瘤生长和转移的应用
EP3013350A4 (fr) * 2013-06-25 2017-02-22 Vaccinex, Inc. Utilisation de molécules d'inhibition de sémaphorine-4d en combinaison avec une thérapie de modulation immunitaire pour inhiber la croissance tumorale et les métastases
AU2014302812B2 (en) * 2013-06-25 2019-07-11 Vaccinex, Inc. Use of semaphorin-4D inhibitory molecules in combination with an immune modulating therapy to inhibit tumor growth and metastases
US11078295B2 (en) 2013-06-25 2021-08-03 Vaccinex, Inc. Use of semaphorin-4D inhibitory molecules with an immune modulating therapy to inhibit tumor growth and metastases
CN109073660A (zh) * 2016-02-29 2018-12-21 麦恩泰科特有限公司 可用于治疗湿性年龄相关性黄斑变性的预测性标志物

Also Published As

Publication number Publication date
CA2762446C (fr) 2021-02-23

Similar Documents

Publication Publication Date Title
JP7345578B2 (ja) 新規抗pd-l1抗体
US11578131B2 (en) Polynucleotides encoding death domain-containing receptor-5 (DR5) binding molecules
US8790652B2 (en) Use of the combination of semaphorin-4D inhibitory molecules and VEGF inhibitory molecules to inhibit angiogenesis
JP6966176B2 (ja) ヒトポリオウイルス受容体(pvr)に特異的な抗体
JP6861418B2 (ja) ヒトt細胞免疫グロブリン及びitimドメイン(tigit)に特異的な抗体
CN110914296B (zh) 改造的Fc片段,包含其的抗体及其应用
KR102357312B1 (ko) Cd20 결합 분자 및 그의 용도
KR102291971B1 (ko) 종양 성장 및 전이를 억제하기 위한 면역 조절 요법과 병용되는 세마포린-4d 억제성 분자의 용도
DK2427212T3 (en) ANTI-CD100 ANTIBODIES AND PROCEDURES FOR USE THEREOF
JP2021522801A (ja) ヒトネクチン4に特異的な抗体
JP2021508676A (ja) 抗tigit抗体並びに治療剤及び診断剤としてのその使用
WO2020168555A1 (fr) Fragment de liaison à l'antigène cd3 et application de celui-ci
KR20190109574A (ko) 암 치료를 위한 항-fam19a5 항체의 용도
JP2012508170A5 (fr)
MX2011004871A (es) Anticuerpos de receptor ii anti-tgf-beta.
WO2021097800A1 (fr) Anticorps multispécifiques anti-pd-l1/anti-b7-h3 et leurs utilisations
KR20220103709A (ko) 항-tigit 항체와의 병용물 형태로 항-ox40 항체를 사용하는 암 치료의 방법
CA2762446C (fr) Utilisation de la combinaison de molecules inhibitrices de la semaphorine-4d et de molecules inhibitrices du facteur de croissance vasculaire endotheliale afin d'inhiber l'angiogenese
US11186632B2 (en) Methods of treating cancer using bifunctional molecules that target growth factors
RU2776121C2 (ru) Новые анти-pd-l1 антитела
JP2024507124A (ja) Cd112rに対する抗体およびその使用
KR20220103105A (ko) 항-tim3 항체와 병용하여 항-ox40 항체를 사용한 암 치료 방법
KR20220103708A (ko) 항-pd1 또는 항-pdl1 항체와의 병용물 형태로 항-ox40 항체를 사용하는 암 치료의 방법
CN117177770A (zh) 使用抗tigit抗体与抗pd1抗体组合治疗癌症的方法

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20161205